See the pitch deck that a hot digital health startup used to stand apart from telehealth rivals and raise millions from VCs
This story is available exclusively to Business Insider subscribers. Become an Insider and start reading now.
- Bright.md, a virtual care startup, just closed its Series C funding round in the middle of the coronavirus pandemic.
- Lockdowns helped drive investor interest in its technology, which speeds up patient visits for doctors.
- It raised an oversubscribed round of $16.7 million, bringing total funding to about $30 million.
- The investor deck reveals the startup’s skepticism of other telemedicine companies.
- Visit Business Insider’s homepage for more stories.
Bright.md, a virtual healthcare startup, just closed its Series C funding under unusual circumstances.
The round opened before the pandemic, but closed at the end of May. In the interim, business boomed for Bright.md. Year-over-year, online visits and new patients grew by 1,200% and 2,000% in April, respectively, according to Ray Costantini, the company’s co-founder and CEO.
Now, visits are already declining — a development Costantini called “a good thing” — but those numbers sat well with potential investors at the time, according to the cofounder.
“Urgency increased,” Costantini told Business Insider. Some investors even wanted to up their contributions retroactively, he said.
When all was said and done, the Portland, Oregon-based company raised $16.7 million, $1.7 million more than it set out to raise. In all, the startup has taken in about $30 million to date. The company declined to disclose its valuation.
Bright.md’s software automates part of doctors’ appointments
Bright.md works differently than some other telehealth companies. Instead of connecting patients with doctors for video visits, its platform SmartExam uses computers and smartphones to automate parts of doctors’ appointments, typically for urgent care and primary care.
The company’s software interviews patients to understand their symptoms, and they’re only given a video or in-person appointments when necessary, according to the company.
Doctors then receive reports, including a transcript of the patient’s interview, and sign off on the platform’s recommendations or choose another course of treatment. Bright.md inputs the data into electronic health records and can take care of referrals, too.
In some ways, Bright.md’s success is a reflection of lockdowns. After coronavirus forced doctors offices to close and people to stay in their homes, companies offering remote care took off. Bright.md itself offers a free tool that helps doctors and hospitals screen patients for coronavirus symptoms.
Telehealth claims in private insurance plans have soared, to 7.5% of claims in March 2020, up from 0.17% in March 2019, according to healthcare data firm FAIR Health. The meteoric rise has caught the eye of venture capital investors, where some top firms are eyeing virtual care’s speedy customer acquisition with enthusiasm.
Read more: VCs from 11 top firms share how coronavirus is transforming their healthcare investing strategies.
‘I think telehealth is boring’
But with that renewed interest comes renewed skepticism, too. In the latest round, investors frequently asked Costantini what separates Bright.md from the other telemedicine companies out there, he said.
“Telehealth looks crowded. Why should we care about you?” Costantini said, recounting a common question during pitches.
For starters, Bright.md’s chief executive said he doesn’t like telemedicine companies very much.
“We often get lumped in as a telehealth company because we sell into the telehealth space by design,” Costantini said. “I think telehealth is boring and commoditized.”
Whereas some telehealth firms sell care directly to consumers and often require video appointments, Bright.md prides itself on cutting down on physicians’ wasted time. They only need 2 minutes, according to Costantini, to consult with SmartExam, saving the rest for patients with “complex clinical needs,” he said.
The model makes sense to investor Seven Peaks Ventures because other telemedicine businesses can end up taking away revenue from their customers, according to Corey Schmid, a general partner. In contrast, Bright.md works within health systems to expand their own doctors’ capacity, she said.
“If a patient calls and says, ‘Hey I have a sinus infection,’ and [providers] have a contract with Teladoc or some other direct-to-consumer, you’re essentially outsourcing that patient to a fleet of doctors that might be in New York or Michigan,” she told Business Insider.
Coronavirus gives new life to old debates in telehealth
There’s a renewed debate among telehealth investors over whether it’s better for companies to integrate more thoroughly with health systems, provide wraparound services like deployment and physician training, or simply help doctors conduct video appointments with patients.
Dr. Krishna Yeshwant, a managing partner at Alphabet’s GV venture fund, said he’s coming around to the simpler model after seeing smaller providers use a startup called Doxy.me, which helps doctors see patients online, in huge numbers over the last couple of months.
Prior to the pandemic, however, he doubted that approach “because to some degree, without those wraparound services, I’ve always felt like telemedicine is a little bit of a commodity,” he told Business Insider.
Read more: 2 investors at Alphabet’s $4.5 billion venture fund share the 3 healthcare companies outside their portfolio that impress them the most.
James Olsen, the founder and managing partner of Concord Health Partners, said there are many early-stage companies that address aspects of a patient’s healthcare encounters, like scheduling, whereas Bright.md’s software can evolve to address a broader set of needs.
Concord helped lead Bright.md’s Series C round with B Capital and Seven Peaks Ventures. The investment firm manages a $50 million fund started by the American Hospital Association.
Here’s the deck that convinced those investors to bet on Bright.md in the middle of a pandemic.